髓内钉类型与股骨近端髓内钉固定术后无菌性翻修风险的关联
基于整合医疗系统髋部骨折登记数据,纳入19215例≥60岁接受头髓钉治疗的髋部骨折患者,比较Gamma钉、INTERTAN钉与TFN/TFNA钉的无菌性翻修风险。多变量Cox分析显示,INTERTAN组8年粗略翻修率2.9%高于TFN/TFNA组1.8%(HR 1.62,95%CI 1.15-2.27,p=0.006),风险增加主要见于长钉(HR 1.83,95%CI 1.16-2.87,p=0.009),Gamma组与TFN/TFNA组无差异。作者认为INTERTAN钉无菌性翻修风险显著更高,需进一步研究是否与植入物独特设计有关。
要点
- INTERTAN组8年无菌性翻修率2.9%高于TFN/TFNA组1.8%(HR 1.62,95%CI 1.15-2.27,p=0.006)。
- INTERTAN长钉翻修风险升高(HR 1.83,95%CI 1.16-2.87,p=0.009),短钉无显著差异(HR 1.36,95%CI 0.87-2.11,p=0.18)。
- Gamma组与TFN/TFNA组无菌性翻修无差异。
核心结论
- 在19215例接受头髓钉治疗的髋部骨折患者中,INTERTAN钉的无菌性翻修风险显著更高。
- 需进一步研究以确定该结果是否与INTERTAN植入物的独特设计有关。
研究设计与样本
- 利用整合医疗系统的髋部骨折登记数据,识别≥60岁且接受Gamma钉、INTERTAN钉或TFN/TFNA钉之一治疗的患者。
- 采用多变量Cox比例风险回归评估不同头髓钉类型与无菌性翻修(主要结局)的风险,并将死亡及与指数骨折无关的翻修作为竞争事件。
- 研究共纳入19215例患者(女性71.4%,白人77.0%),其中Gamma钉组4421例,INTERTAN组2350例,TFN/TFNA组12444例。
- 对年龄、性别、种族或民族、体重指数、吸烟状态、美国麻醉医师协会分级、麻醉类型、Elixhauser合并症及主刀医生等潜在混杂因素进行了识别和控制。
主要发现
- 在涉及所有长度钉的多变量分析中,INTERTAN组较TFN/TFNA组无菌性翻修风险更高(8年粗略翻修率2.9% vs 1.8%;HR 1.62,95%CI 1.15-2.27;p=0.006)。
- INTERTAN钉增加的风险主要见于长钉(HR 1.83,95%CI 1.16-2.87;p=0.009),而非短钉(HR 1.36,95%CI 0.87-2.11;p=0.18)。
- Gamma组与TFN/TFNA组之间未观察到无菌性翻修差异。
关键数值与推荐
- INTERTAN组与TFN/TFNA组比较:8年粗略翻修率2.9% vs 1.8%,HR 1.62(95%CI 1.15-2.27),p=0.006。
- INTERTAN长钉与TFN/TFNA长钉比较:HR 1.83(95%CI 1.16-2.87),p=0.009。
- INTERTAN短钉与TFN/TFNA短钉比较:HR 1.36(95%CI 0.87-2.11),p=0.18。
- 证据等级:治疗性III级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以确定这些结果是否与INTERTAN植入物的独特设计有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the majority of intertrochanteric femoral fractures in the United States are now treated with cephalomedullary nailing, it remains uncertain whether differences in clinical performance by nail type exist. The purpose of this study was to compare the aseptic revision rates associated with the 3 most commonly utilized cephalomedullary nails in the United States today: the Gamma nail (Stryker), the INTERTAN (Smith+Nephew), and the Trochanteric Fixation Nail/Trochanteric Fixation Nail Advanced (TFN/TFNA; DePuy Synthes). METHODS: Using an integrated health-care system's hip fracture registry, patients ≥60 years of age who were treated with 1 of these 3 commonly used cephalomedullary nail devices were identified. Potential confounders were identified and controlled for, including age, gender, race or ethnicity, body mass index, smoking status, American Society of Anesthesiologists classification, anesthesia type, Elixhauser comorbidities, and the operating surgeon. Multivariable Cox proportional-hazards regression was used to evaluate the risk of aseptic revision (the primary outcome measure) by cephalomedullary nail type, with mortality and revisions unrelated to the index fracture considered as competing events. RESULTS: There were 19,215 patients included in the study sample (71.4% female, 77.0% White), including 4,421 in the Gamma nail group, 2,350 in the INTERTAN nail group, and 12,444 in the TFN/TFNA nail group. In the multivariable analysis involving nails of all lengths, the INTERTAN group was found to have a higher risk of aseptic revision compared with the TFN/TFNA group (8-year crude revision rate, 2.9% compared with 1.8%; hazard ratio [HR], 1.62 [95% confidence interval (CI), 1.15 to 2.27]; p = 0.006). The increased risk associated with the INTERTAN nail was primarily seen among the long nails (HR, 1.83 [95% CI, 1.16 to 2.87]; p = 0.009) rather than the short nails (HR, 1.36 [95% CI, 0.87 to 2.11]; p = 0.18). There were no differences in aseptic revision observed between the Gamma group and the TFN/TFNA group. CONCLUSIONS: In this study of 19,215 patients with a hip fracture treated with cephalomedullary nailing, the INTERTAN nail was found to have a significantly higher risk of aseptic revision. Further research is required to determine whether these results could be related to the unique design of this implant. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Okike K, Chang RN, Royse KE, et al. Association Between Nail Type and Aseptic Revision Risk After Cephalomedullary Nailing for Hip Fracture. J Bone Joint Surg Am. 2024. PMID: 39812725. doi:10.2106/JBJS.24.00390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。